This chapter explores how to regulate programmed cell death and its relevance in cancer therapy. It points to the need of investigate mechanisms of cell death, like apoptosis, necroptosis, and, more recently, exposed ferroptosis, while creating approaches for the treatment of malignant diseases. In spite of progress in the field of targeted therapies, cancer is still a main cause of death due to the incapability of the cancer cells to undergo apoptosis. The chapter highlights the significance of adopting complex approaches that encompass multiple types of cell death occurring within both the cells and the tumor microenvironment. Of note are the functions of oncogenes and tumor suppressor genes in the regulation of cellular death processes, the specific role of apoptosis in the tumor formation process, and the possibility of treatment to increase cell death in neoplastic cells. There is metastasis of genes that are critical for apoptosis such as the TP53 tumor suppressor gene, along with the presence of an over expression of anti-apoptotic proteins. Examples of this would include Bcl-2 and IAPs, which protect multiple types of cancer cells against stimuli required for cell death. The role of immunotherapy and combination therapies is described as emerging strategies to enhance the efficacy of treatments. The document also deals with the problem of resistance to the induction of cell death and the necessity for further clinical studies of new therapeutic agents in practice. In summary, it highlights the diversity in cancer biology and the need for a paradigm shift to achieve tumor cell death.